Based on six recent retrospective analyses comparing the gonadotropin-releasing hormone (GnRH) antagonist degarelix against the traditional luteinizing hormone-releasing hormone (LHRH) agonists (i.e. Zoladex, Lupron etc.) men with advanced prostate cancer experienced improved disease control, fewer instances of urinary infections, and a lower risk of cardiovascular events.
The six analyses compared data from randomized trials that included a sample of 2328 men who took either degarelix or an LHRH agonist—leuprolide acetate or goserelin—for three months to a year. The various findings of the six studies was presented in separate abstracts during the most recent annual meeting of the American Urological Association (AUA.
The two different groups of men were balanced for items such as age, disease stage, and levels of testosterone and prostate-specific antigen (PSA), said Neal D. Shore, MD, medical director of the Carolina Urologic Research Center in Myrtle Beach, S